Palbociclib
Palbociclib is the first representative of the new drug class of cyclin-dependent kinase inhibitors. This effect limits cell proliferation (cell growth and division). It is used as an antineoplastic agent in advanced or metastatic breast cancer (in combination with aromatase inhibitors or fulvestrant).
Description
Formula
Molecular weight
Molecular size
Controlled Substance
Precursor
Indications
Your Contact
Marius Hang
International Division
Director API Export
Rheinstr. 49
55218 Ingelheim
Germany
-
Disclaimer
The information contained herein is the proprietary information of Midas Pharma GmbH and its affiliates. This information is provided to you solely for your evaluation, to determine your interest in a potential business relationship with Midas Pharma GmbH and/or its affiliates. Midas Pharma GmbH excludes any express or implied representations, guarantees or warranties of whatsoever nature, including but not limited to the warranties for the completeness or accuracy of the information provided herein.
No information provided herein – including any reference to any product or service – constitutes an offer for sale, or shall be construed as representing an offer for sale. In particular, nothing herein should be construed as a promotion or advertisement for any product, or for the use of any product, that infringes valid patents and/or is not authorized by the laws and regulations of your country of residence.